Emerging Nanotechnology in Chronic Respiratory Diseases

Pandey, P; Mehta, M; Shukla, S; Wadhwa, R; Singhvi, G; Chellappan, DK; Satija, S; Gupta, G; Awasthi, R; Prasher, P; Hansbro, PM; Dua, K; Dureja, H

Emerging Nanotechnology in Chronic Respiratory Diseases

Pandey, P Mehta, M Shukla, S Wadhwa, R Singhvi, G Chellappan, DK Satija, S

Gupta, G Awasthi, R Prasher, P Hansbro, PM Dua, K

Dureja, H

Permalink

Publisher:: Springer International Publishing
Publication Type:: Chapter
Citation:: Nanoformulations in Human Health, 2020, pp. 449-468
Issue Date:: 2020

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

The embargo period expires on 31 Jul 2022

Adobe PDF

Download Accepted Manuscript VersionAdobe PDF (714.45 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Pandey, P
dc.contributor.author	Mehta, M
dc.contributor.author	Shukla, S
dc.contributor.author	Wadhwa, R
dc.contributor.author	Singhvi, G
dc.contributor.author	Chellappan, DK
dc.contributor.author	Satija, S https://orcid.org/0000-0003-4702-6534
dc.contributor.author	Gupta, G
dc.contributor.author	Awasthi, R
dc.contributor.author	Prasher, P
dc.contributor.author	Hansbro, PM
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Dureja, H
dc.date.accessioned	2021-01-06T05:33:23Z
dc.date.available	2021-01-06T05:33:23Z
dc.date.issued	2020
dc.identifier.citation	Nanoformulations in Human Health, 2020, pp. 449-468
dc.identifier.isbn	9783030418571
dc.identifier.uri	http://hdl.handle.net/10453/145113
dc.description.abstract	A large population, including people of all age groups, is suffering from chronic respiratory diseases worldwide. Asthma, chronic obstructive pulmonary disease, occupational lung diseases, cystic fibrosis, etc. are the most common of these diseases and are noncurable with conventional and currently available therapies. Nanotechnology is emerging as a great therapeutic promise in different spheres including drug delivery systems and is becoming the technology of choice nowadays. The administration of drugs via inhalation helps in avoiding the first-pass metabolism by targeted delivery to the affected site. It has been observed that there is a huge diversity in nanotechnology being used in pulmonary diseases, and thus safety assessment is a challenging as well as important task. The present review focuses on some of the major emerging nanotechnologies for chronic pulmonary diseases and includes some of the latest studies in the field of nanomedicines.
dc.format.extent	21
dc.language	en
dc.publisher	Springer International Publishing
dc.relation.ispartof	Nanoformulations in Human Health
dc.relation.hasversion	Accepted Manuscript Version	en
dc.relation.isbasedon	10.1007/978-3-030-41858-8_20
dc.rights	info:eu-repo/semantics/embargoedAccess
dc.title	Emerging Nanotechnology in Chronic Respiratory Diseases
dc.type	Chapter
utslib.for	1102 Cardiorespiratory Medicine and Haematology
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	open_access	*
pubs.consider-herdc	false
utslib.copyright.embargo	2022-07-31T00:00:00+1000Z
dc.date.updated	2021-01-06T05:33:21Z
pubs.place-of-publication	Singapore
pubs.publication-status	Published
dc.location	Singapore

Abstract:

A large population, including people of all age groups, is suffering from chronic respiratory diseases worldwide. Asthma, chronic obstructive pulmonary disease, occupational lung diseases, cystic fibrosis, etc. are the most common of these diseases and are noncurable with conventional and currently available therapies. Nanotechnology is emerging as a great therapeutic promise in different spheres including drug delivery systems and is becoming the technology of choice nowadays. The administration of drugs via inhalation helps in avoiding the first-pass metabolism by targeted delivery to the affected site. It has been observed that there is a huge diversity in nanotechnology being used in pulmonary diseases, and thus safety assessment is a challenging as well as important task. The present review focuses on some of the major emerging nanotechnologies for chronic pulmonary diseases and includes some of the latest studies in the field of nanomedicines.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/145113